Clinical trial / 2016
Fasting up to 72 hours around platinum-based chemotherapy was feasible and safe in cancer patients.
Researchers tested dose-escalation of fasting (24, 48, or 72 hours around chemotherapy) in 20 cancer patients receiving platinum-based regimens. Feasibility criteria were met, with fasting-related toxicities limited to grade 2 or lower (most commonly fatigue, headache, and dizziness). Leukocyte DNA damage showed a non-significant reduction in subjects fasting ≥48 hours (p = 0.08), and a non-significant trend toward less grade 3 or 4 neutropenia was observed in the 48 and 72 hour cohorts versus the 24 hour cohort (p = 0.17). IGF-1 levels decreased by 30%, 33%, and 8% in the 24, 48, and 72 hour fasting cohorts, respectively, after the first fasting period.
- Study type
- Dose-escalation feasibility trial
- Who was studied
- 20 cancer patients receiving platinum-based chemotherapy (median age 61, 85% women)
- What was measured
- Feasibility, safety/toxicity, oxidative stress/DNA damage in leukocytes, and fasting biomarkers (IGF-1, glucose, insulin, ketones, IGFBPs)
THE PAPER
Safety and feasibility of fasting in combination with platinum-based chemotherapy.
Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. BMC Cancer, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.